Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:fragrance
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Merck_Serono
|
| gptkbp:activities |
low molecular weight heparin
|
| gptkbp:appointed_by |
gptkb:hospital
subcutaneous injection patients themselves |
| gptkbp:approves |
gptkb:1993
many countries |
| gptkbp:brand |
gptkb:enoxaparin_sodium
|
| gptkbp:caused_by |
injection site reactions
hypersensitivity reactions heparin-induced thrombocytopenia |
| gptkbp:contraindication |
thrombocytopenia
active bleeding severe renal impairment |
| gptkbp:developed_by |
gptkb:Sanofi
|
| gptkbp:dosage_form |
injection
|
| https://www.w3.org/2000/01/rdf-schema#label |
Clexane
|
| gptkbp:ingredients |
gptkb:enoxaparin
|
| gptkbp:interacts_with |
antiplatelet agents
other anticoagulants NSAI Ds |
| gptkbp:is |
oral medication
|
| gptkbp:is_available_in |
gptkb:various_countries
|
| gptkbp:is_available_on |
vials
pre-filled syringes |
| gptkbp:is_considered |
safe for short-term use
effective for prevention of clots effective for treatment of clots |
| gptkbp:is_monitored_by |
anti-Xa levels
platelet count |
| gptkbp:is_part_of |
anticoagulant therapy
|
| gptkbp:is_used_by |
patients at risk of thrombosis
|
| gptkbp:is_used_for |
preventing blood clots
|
| gptkbp:is_used_in |
hospital settings
outpatient settings |
| gptkbp:marketed_as |
various brand names
|
| gptkbp:requires |
gptkb:battle
|
| gptkbp:shelf_life |
usually 2 years
|
| gptkbp:side_effect |
bruising
bleeding pain at injection site |
| gptkbp:storage |
room temperature
|
| gptkbp:suitable_for |
lactation without medical advice
pregnancy without medical advice |
| gptkbp:used_in |
gptkb:hospital
gptkb:unstable_angina gptkb:deep_vein_thrombosis pulmonary embolism |